Page last updated: 2024-10-27

flecainide and Tachycardia, Ventricular

flecainide has been researched along with Tachycardia, Ventricular in 134 studies

Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).

Tachycardia, Ventricular: An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation).

Research Excerpts

ExcerptRelevanceReference
"The aim of this review is to evaluate the available data on efficacy and safety of flecainide in all the spectrum of its indications including cardioversion of recent-onset AF, sinus rhythm maintenance in paroxysmal AF and management of ventricular tachyarrhythmias."8.89Flecainide acetate for the treatment of atrial and ventricular arrhythmias. ( Apostolakis, S; Breithardt, G; Fabritz, L; Kirchhof, P; Oeff, M; Tebbe, U, 2013)
"Thirty-three patients received flecainide because of exercise-induced ventricular arrhythmias despite conventional (for different reasons, not always optimal) therapy (median age 25 years; range 7 to 68 years; 73% female)."7.77Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. ( Bhuiyan, ZA; Fish, FA; Haïssaguerre, M; Kannankeril, PJ; Knollmann, BC; Krahn, AD; Laborderie, J; Leenhardt, A; Sacher, F; Shimizu, W; Sumitomo, N; van der Veen, MJ; van der Werf, C; Viskin, S; Watanabe, H; Wilde, AA; Willems, AR, 2011)
"A 37-year-old man with symptomatic acute atrial fibrillation and a low-voltage electrocardiogram was treated with flecainide intravenously."7.73[Life-threatening ventricular tachycardia during flecainide treatment for symptomatic atrial fibrillation in a patient with a structural cardiac disorder]. ( Rienstra, M; van Gelder, IC; van Veldhuisen, DJ; Wiesfeld, AC, 2006)
"The flecainide test is widely used in Brugada syndrome."7.72Flecainide test in Brugada syndrome: a reproducible but risky tool. ( Ceriotti, C; Galimberti, P; Gasparini, M; Mantica, M; Napolitano, C; Priori, SG; Simonini, S, 2003)
"The Cardiac Arrhythmia Suppression Trial has shown that flecainide was associated with an increased incidence of sudden cardiac death in postinfarction patients."7.69Reentrant arrhythmias in the subacute infarction period. The proarrhythmic effect of flecainide acetate on functional reentrant circuits. ( Assadi, MA; Avitable, MJ; Caref, EB; el-Sherif, N; Isber, N; Ndrepepa, G; Patel, AI; Restivo, M; Yin, H, 1995)
"This study suggests that flecainide and beta-blockers association is complementary to implantable cardioverter-defibrillator and catheter ablation and is safe for treating persistent symptomatic VA in patients with ARVC."5.72Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy. ( Badenco, N; Duthoit, G; Frank, R; Gandjbakhch, E; Hidden-Lucet, F; Himbert, C; Laredo, M; Maupain, C; Rolland, T; Waintraub, X, 2022)
"No evidence of ischemic heart disease was detected."5.30Class IC antiarrhythmic drugs, flecainide and pilsicainide, produce ST segment elevation simulating inferior myocardial ischemia. ( Ito, H; Nakamura, W; Segawa, K; Tanaka, S; Yoshimoto, N, 1998)
"This report presents the case of a young man of 24 years old with Asperger syndrome who ingest quantities of medication whose flecainide."5.05[Flecainid intoxication: Evolution, complications and care of]. ( Bensussan, H; Mhamdi, K, 2020)
"The aim of this review is to evaluate the available data on efficacy and safety of flecainide in all the spectrum of its indications including cardioversion of recent-onset AF, sinus rhythm maintenance in paroxysmal AF and management of ventricular tachyarrhythmias."4.89Flecainide acetate for the treatment of atrial and ventricular arrhythmias. ( Apostolakis, S; Breithardt, G; Fabritz, L; Kirchhof, P; Oeff, M; Tebbe, U, 2013)
"Flecainide is a class Ic antidysrhythmic agent used to prevent and treat both ventricular and supraventricular tachycardias, including atrial fibrillation, atrioventricular nodal re-entrant tachycardia, and Wolff-Parkinson-White syndrome."3.96The Case of Flecainide Toxicity: What to Look for and How to Treat. ( Newson, JM; Santos, CD; Todd, BR; Walters, BL, 2020)
" Her pregnancy was uncomplicated, and she was medically managed with metoprolol, flecainide, and verapamil."3.96Catecholaminergic polymorphic ventricular tachycardia in pregnancy: a case report. ( Contag, S; Schumer, A, 2020)
"Dronedarone was the only anti-arrhythmic drug with significantly lower risk for arrhythmic death, sustained ventricular arrhythmia or ICD implantation than sotalol among patients with atrial fibrillation."3.88Ventricular arrhythmia and death among atrial fibrillation patients using anti-arrhythmic drugs. ( Friberg, L, 2018)
"Antiarrhythmic agents which belong to class Ia (quinidine) and Ic (flecainide) reportedly increase propensity to ventricular tachyarrhythmia, whereas class Ib agents (lidocaine and mexiletine) are recognized as safe antiarrhythmics."3.80Effects of Na+ channel blockers on extrasystolic stimulation-evoked changes in ventricular conduction and repolarization. ( Osadchii, OE, 2014)
"Thirty-three patients received flecainide because of exercise-induced ventricular arrhythmias despite conventional (for different reasons, not always optimal) therapy (median age 25 years; range 7 to 68 years; 73% female)."3.77Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. ( Bhuiyan, ZA; Fish, FA; Haïssaguerre, M; Kannankeril, PJ; Knollmann, BC; Krahn, AD; Laborderie, J; Leenhardt, A; Sacher, F; Shimizu, W; Sumitomo, N; van der Veen, MJ; van der Werf, C; Viskin, S; Watanabe, H; Wilde, AA; Willems, AR, 2011)
"A 37-year-old man with symptomatic acute atrial fibrillation and a low-voltage electrocardiogram was treated with flecainide intravenously."3.73[Life-threatening ventricular tachycardia during flecainide treatment for symptomatic atrial fibrillation in a patient with a structural cardiac disorder]. ( Rienstra, M; van Gelder, IC; van Veldhuisen, DJ; Wiesfeld, AC, 2006)
"Using tissue Doppler echocardiography, we studied how these contractile variables change on induction of the characteristic ST-segment changes of Brugada syndrome by flecainide challenge."3.72Delay in right ventricular activation contributes to Brugada syndrome. ( de Groot, IK; Sogaard, P; Tan, HL; Tukkie, R; Vleugels, J; Wilde, AA, 2004)
"The flecainide test is widely used in Brugada syndrome."3.72Flecainide test in Brugada syndrome: a reproducible but risky tool. ( Ceriotti, C; Galimberti, P; Gasparini, M; Mantica, M; Napolitano, C; Priori, SG; Simonini, S, 2003)
"The class IC antiarrhythmic drug flecainide has been shown to be ineffective for the treatment of ventricular arrhythmias in some patients who have had a prior myocardial infarction and sometimes even provoke arrhythmias (proarrhythmic effect)."3.69Electrophysiological effects of flecainide on anisotropic conduction and reentry in infarcted canine hearts. ( Coromilas, J; Dillon, SM; Saltman, AE; Waldecker, B; Wit, AL, 1995)
"The Cardiac Arrhythmia Suppression Trial has shown that flecainide was associated with an increased incidence of sudden cardiac death in postinfarction patients."3.69Reentrant arrhythmias in the subacute infarction period. The proarrhythmic effect of flecainide acetate on functional reentrant circuits. ( Assadi, MA; Avitable, MJ; Caref, EB; el-Sherif, N; Isber, N; Ndrepepa, G; Patel, AI; Restivo, M; Yin, H, 1995)
"The Elimination of Ventricular Premature Beats with Catheter Ablation versus Optimal Antiarrhythmic Drug Treatment (ECTOPIA) trial is a randomized, multicenter, prospective clinical trial to compare the efficacy of catheter ablation versus optimal AAD treatment with sotalol or flecainide/verapamil."2.94Elimination of Benign Ventricular Premature Beats or Ventricular Tachycardia with Catheter Ablation versus Two Different Optimal Antiarrhythmic Drug Treatment Regimens (Sotalol or Verapamil/Flecainide). ( Adiyaman, A; Beukema, RJ; de Jong, JSSG; Delnoy, PPHM; Elvan, A; Haanschoten, DM; Khan, M; Otten, AM; Ramdat Misier, AR; Smit, JJJ; Szili-Torok, T; Ter Bekke, RMA; Vernooy, K, 2020)
"To determine whether flecainide dosed to therapeutic levels and added to β-blocker therapy is superior to β-blocker therapy alone for the prevention of exercise-induced arrhythmias in CPVT."2.84Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial. ( Batra, AS; Carboni, MP; Cerrone, M; Chen, H; Dzurik, MV; Ely, EW; Etheridge, SP; Fairbrother, DL; Fountain, D; Kannankeril, PJ; Kanter, RJ; Kaufman, ES; Kertesz, NJ; Knollmann, BC; Moore, JP; Priori, SG; Ro, PS; Roden, DM; Saarel, EV, 2017)
"The test may also induce premature ventricular complexes (PVCs) in individuals without Brugada pattern, the clinical relevance of which is little known."2.82Malignant Purkinje ectopy induced by sodium channel blockers. ( Bernus, O; Cheniti, G; Combes, N; Derval, N; Duchateau, J; Escande, W; Gandjbakhch, E; Gourraud, JB; Haissaguerre, M; Hermida, JS; Hocini, M; Jaïs, P; Krisai, P; Lavergne, T; Martins, R; Maury, P; Merino, JL; Nademanee, K; Pambrun, T; Pasquié, JL; Postema, PG; Probst, V; Sacher, F; Surget, E; Vigmond, E, 2022)
"This multicenter study suggests that oral flecainide therapy is an effective and safe means of suppressing VAs in patients with ATS with KCNJ2 mutations, though the U-wave amplitude remained unchanged by flecainide."2.80Efficacy and safety of flecainide for ventricular arrhythmias in patients with Andersen-Tawil syndrome with KCNJ2 mutations. ( Aiba, T; Anzai, T; Hayashi, H; Horie, M; Ishibashi, K; Ishihara, M; Kamakura, S; Kimura, H; Kusano, K; Miyamoto, K; Miyamoto, Y; Nakajima, I; Noda, T; Ogawa, H; Ohno, S; Okamura, H; Shimizu, W; Tanioka, Y; Tsuboi, I; Tsuchiya, T; Yasuda, S; Yasuoka, C; Yoshida, Y, 2015)
"Flecainide was reported to reduce exercise-induced ventricular arrhythmias (EIVA) in patients with ryanodine receptor-associated CPVT."2.78Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia. ( Blich, M; Boulos, M; Gepstein, L; Khoury, A; Lorber, A; Marai, I; Suleiman, M, 2013)
" Despite careful precautions, serious proarrhythmias, the major limiting side effect of dofetilide, still occurred during long-term follow-up."2.73Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function. ( Bauman, JL; Kehoe, RF; Leal, S; Mykytsey, A; Razminia, M; Saleem, M; Wang, T; Zheutlin, T, 2007)
"Amiodarone has a more favourable therapeutic profile than flecainide and propafenone in these patients, having less tendency to worsen heart failure."2.67A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Antiarrhythmic Drug Evaluation Group (A.D.E.G.). ( , 1992)
"Flecainide did not increase the risk of all side effects (RR = 0."2.61Safety and efficacy of flecainide for patients with catecholaminergic polymorphic ventricular tachycardia: A systematic review and meta-analysis. ( Li, J; Wang, G; Wang, Y; Zhao, N; Zhong, S, 2019)
"Flecainide has improved CPVT outcomes and will likely have broader clinical indications in the near future."2.55Catecholaminergic polymorphic ventricular tachycardia: a model for genotype-specific therapy. ( Roston, TM; Sanatani, S; Van Petegem, F, 2017)
"Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inheritable cardiac disorder associated with exercise- and stress-induced sudden death in young individuals."2.53Clinical Challenges in Catecholaminergic Polymorphic Ventricular Tachycardia. ( Imberti, JF; Mazzanti, A; Priori, SG; Underwood, K, 2016)
"Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmogenic disease that can cause sudden cardiac death due to ventricular fibrillation (VF)."2.47Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature. ( Bittner, A; Dechering, DG; Eckardt, L; Köbe, J; Kotthoff, S; Mönnig, G; Muszynski, A; Pott, C; Reinke, F; Schulze-Bahr, E; Wasmer, K; Zellerhoff, S, 2011)
"Long QT syndrome was identified postnatally on the electrocardiogram, and was confirmed by genetic testing which showed a mutation in the KCNH2 gene (p."2.45Fetal ventricular tachycardia secondary to long QT syndrome treated with maternal intravenous magnesium: case report and review of the literature. ( Gill, H; Maxwell, D; Rosenthal, E; Simpson, JM, 2009)
"Flecainide is a Class IC antiarrhythmic agent whose primary electrophysiologic effect is a slowing of conduction in a wide range of cardiac tissues."2.39Flecainide. ( Falk, RH; Fogel, RI, 1994)
"Patients with unexplained ventricular arrhythmias (UVA) were identified as those with no structural heart disease on echocardiogram, no obstructive coronary disease, and no clear diagnostic features on ECG."1.91Diagnostic evaluation of unexplained ventricular tachyarrhythmias in younger adults. ( Kistler, P; Ling, LH; Mariani, J; Patel, H; Prabhu, S; Shirwaiker, A; Sugamar, H; Voskoboinik, A; William, J; Xiao, X, 2023)
"Polymorphic ventricular tachycardia (PMVT) is a rare genetic disease associated with structurally normal hearts which in 8% of cases can lead to sudden cardiac death, typically exercise-induced."1.91Personalized medicine in the dish to prevent calcium leak associated with short-coupled polymorphic ventricular tachycardia in patient-derived cardiomyocytes. ( Charrabi, A; Chen, S; Cheung, JW; Colombani, S; Evans, T; Jaffré, F; Lacampagne, A; Lerman, BB; Marks, AR; Meli, AC; Pasquié, JL; Reiken, S; Sittenfeld, LR; Sleiman, Y, 2023)
"Flecainide is a class 1c anti-arrhythmic drug that has demonstrated therapeutic efficacy in treating CPVT."1.91Insights on the mechanism of flecainide in catecholaminergic polymorphic ventricular tachycardia. ( Davidson, R; Medeiros, M, 2023)
"This study suggests that flecainide and beta-blockers association is complementary to implantable cardioverter-defibrillator and catheter ablation and is safe for treating persistent symptomatic VA in patients with ARVC."1.72Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy. ( Badenco, N; Duthoit, G; Frank, R; Gandjbakhch, E; Hidden-Lucet, F; Himbert, C; Laredo, M; Maupain, C; Rolland, T; Waintraub, X, 2022)
"A novel familial arrhythmia syndrome, cardiac ryanodine receptor (RyR2) calcium release deficiency syndrome (CRDS), has recently been described."1.72Provocation Testing and Therapeutic Response in a Newly Described Channelopathy: RyR2 Calcium Release Deficiency Syndrome. ( Chen, SRW; Dreau, HMP; Ginks, MR; Guo, W; Li, Y; McGuire, K; Ormerod, JOM; Ormondroyd, E; Rajappan, K; Sarton, CNS; Taylor, J; Taylor, JC; Wang, R; Watkins, H; Wei, J, 2022)
" A medication episode was defined as a timeframe in which the highest dosage at a fixed level of a single drug was used in a patient."1.62The Efficacy of Anti-Arrhythmic Drugs in Children With Idiopathic Frequent Symptomatic or Asymptomatic Premature Ventricular Complexes With or Without Asymptomatic Ventricular Tachycardia: a Retrospective Multi-Center Study. ( Bertels, RA; Blom, NA; Filippini, LH; Kammeraad, JAE; Knobbe, I; Kuipers, IM; Zeelenberg, AM, 2021)
"Flecainide was added to the treatment regime."1.48Can flecainide totally eliminate bidirectional ventricular tachycardia in pediatric patients with Andersen-Tawil syndrome? ( Ergül, Y; Onan, SH; Özgür, S; Tuzcu, V, 2018)
"Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal hereditary disease characterized by complex ventricular arrhythmias provoked by exercise or emotional stress and by a high mortality rate in young individuals."1.48Efficacy of ivabradine to control ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia. ( Klug, D; Vaksmann, G, 2018)
"Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited disease characterized by polymorphic or bidirectional ventricular arrhythmias (VA) triggered by physical or emotional stress in young people with a structurally normal heart."1.48Flecainide Reduces Ventricular Arrhythmias in Patients With Genotype RyR2-positive Catecholaminergic Polymorphic Ventricular Tachycardia. ( Álvarez Acosta, L; Brugada Terradellas, J; Brugada Terradellas, R; Caballero Dorta, E; Campuzano Larrea, O; Groba Marco, MDV; Hernández Afonso, JS; Pérez, G; Wangüemert Pérez, F, 2018)
"Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia syndrome characterized by fatal ventricular arrhythmias in structurally normal hearts during β-adrenergic stimulation."1.43In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia. ( Clancy, CE; Grandi, E; Jeng, MT; Miyake, CY; Moreno, JD; Noskov, SY; Vaughn-Behrens, SB; Wehrens, XH; Yang, PC, 2016)
"Catecholaminergic polymorphic ventricular tachycardia was diagnosed by electrocardiogram at cardiac arrest (n=2), or provocation test, either by catecholamine infusion test (n=6) or exercise test (n=2)."1.43Clinical and genetic profile of catecholaminergic polymorphic ventricular tachycardia in Hong Kong Chinese children. ( Chung, BH; Liu, AP; Lun, KS; Yu, TC; Yung, TC, 2016)
"Flecainide testing was performed at each follow-up visits ≤6 months."1.42Brugada Syndrome Phenotype Elimination by Epicardial Substrate Ablation. ( Berruezo, A; Brugada, J; Ciconte, G; Giannelli, L; Manguso, F; Pappone, C; Santinelli, V; Vicedomini, G, 2015)
"Unexplained cardiac arrest (UCA) can be caused by low-penetrance genetic disorders."1.42Diagnostic Approach to Unexplained Cardiac Arrest (from the FIVI-Gen Study). ( Álvarez, M; Cózar, R; Domingo, D; Fernández Pastor, J; Gimeno, JR; Grima, EZ; Heras, RP; Jiménez-Jáimez, J; Mazuelos, F; Monserrat, L; Moriña, P; Ortiz-Genga, M; Peinado, R; Sánchez Muñoz, JJ; Segura, F; Tercedor, L, 2015)
"The diagnosis of ventricular tachycardia was made early in her pregnancy course but the patient had symptoms three months earlier."1.42Right ventricular outflow tract tachycardia worsened during pregnancy. ( Amoussou, M; Kambiré, Y; Konaté, L; Millogo, GR; Nebié, LV; Niakara, A; Sib, E, 2015)
"Flecainide was initiated because of significant ventricular arrhythmias (n = 8), syncope (n = 3), or cardiac arrest (n = 1)."1.39Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia. ( Adler, A; Bhuiyan, ZA; Bikker, H; Horie, M; Kannankeril, PJ; Knollmann, BC; Minamino, T; Roses-Noguer, F; Rosso, R; Sumitomo, N; Till, J; van der Werf, C; Veltmann, C; Viskin, S; Watanabe, H; Wilde, AA, 2013)
"Catecholaminergic polymorphic ventricular tachycardia was diagnosed with the aid of an implantable loop recorder."1.39A de novo novel cardiac ryanodine mutation (Ser4155Tyr) associated with catecholaminergic polymorphic ventricular tachycardia. ( Anastasakis, A; Kotsaka, X; Luria, D; Mantziari, L; Paraskevaidis, S; Styliadis, IH; Vassilikos, V, 2013)
"Control animals developed premature ventricular complexes (PVCs) followed by ventricular tachycardia, which terminated in VF in 5 of the 8 dogs."1.39HBI-3000 prevents secondary sudden cardiac death. ( Lee, JY; Lucchesi, BR, 2013)
"Flecainide is a class 1C antiarrhythmic drug especially used for the management of supraventricular arrhythmia."1.39Arrhythmogenic effect of flecainide toxicity. ( Bonnefoy, E; Courand, PY; Kirkorian, G; Mullier, A; Ranc, S; Sibellas, F, 2013)
"Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited condition associated with ventricular tachycardia (VT) triggered by exercise or sympathetic stress."1.38Flecainide suppresses defibrillator-induced storming in catecholaminergic polymorphic ventricular tachycardia. ( Choi, JJ; Hong, RA; Jittirat, A; Rivera, KK, 2012)
"Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an arrhythmogenic disease for which electrophysiological studies (EPS) have shown to be of limited value."1.37Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene. ( Antzelevitch, C; Arad, M; Belhassen, B; Bhuiyan, ZA; El-Ani, D; Eldar, M; Fogelman, R; Glikson, M; Luria, D; Mannens, MM; Nof, E; Rosso, R; Viskin, S; Wilde, AA, 2011)
"Propafenone was stereoselective, with R-propafenone suppressing waves more potently than S-propafenone (IC(50): R-propafenone 2 ± 0."1.37Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin. ( Galimberti, ES; Knollmann, BC, 2011)
"Catecholaminergic polymorphic ventricular tachycardia (CPVT) is caused by mutations in the cardiac ryanodine receptor (RyR2) or calsequestrin (Casq2) and can be difficult to treat."1.37Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. ( Faggioni, M; Hasdemir, C; Hwang, HS; Knollmann, BC; Laver, D; Mehra, D; Turhan, K; Yin, H, 2011)
"Palpitations in pregnancy are not an uncommon complaint."1.35Paroxysmal bidirectional ventricular tachycardia with tachycardiomyopathy in a pregnant woman. ( Cobbe, SM; McGavigan, AD; Walker, NL, 2009)
"Bidirectional ventricular tachycardia (BVT), although a rare arrhythmia in the general population, is frequently observed in patients with Andersen-Tawil syndrome and long QT interval."1.35Flecainide suppresses bidirectional ventricular tachycardia and reverses tachycardia-induced cardiomyopathy in Andersen-Tawil syndrome. ( Gonzalez, MD; Kalaizich, L; Pellizzón, OA; Ptácek, LJ; Tristani-Firouzi, M, 2008)
"We discovered that flecainide prevents arrhythmias in a mouse model of CPVT by inhibiting cardiac ryanodine receptor-mediated Ca(2+) release and thereby directly targeting the underlying molecular defect."1.35Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. ( Chopra, N; Davies, SS; Duff, HJ; Hwang, HS; Knollmann, BC; Laver, D; Roach, DE; Roden, DM; Watanabe, H; Wilde, AA, 2009)
"He had incomplete left bundle branch block with left-axis deviation."1.31His-Purkinje system reentry as a proarrhythmic effect of flecainide. ( Barra, N; Cellarier, G; Chalvidan, T; Colin, R; Deharo, JC; Djiane, P; Peyre, JP; Savon, N, 2000)
"Propranolol or flecainide was added to the treatment protocol for two patients who did not respond to verapamil alone."1.31Idiopathic sustained left ventricular tachycardia in pediatric patients. ( Iwamoto, M; Kobayashi, H; Niimura, I; Nishizawa, T; Sakon, T; Shibata, T; Takigiku, K; Yasui, K; Yokoyama, U, 2001)
"Verapamil was infused into the superior vena cava over 15-20 min."1.30Effects of verapamil in ventricular tachycardias. An experimental and clinical study. ( Casanova, JM; De Micheli, A; Iturralde, P; Medrano, GA, 1997)
"Flecainide acetate is a potent class Ic anti-arrhythmic drug with major sodium channel blocking actions."1.30Survival in a case of life-threatening flecainide overdose. ( Bourke, JP; Gascoigne, AD; Hanley, NA, 1998)
"No evidence of ischemic heart disease was detected."1.30Class IC antiarrhythmic drugs, flecainide and pilsicainide, produce ST segment elevation simulating inferior myocardial ischemia. ( Ito, H; Nakamura, W; Segawa, K; Tanaka, S; Yoshimoto, N, 1998)
"Patient 1 had frequent episodes of paroxysmal atrial fibrillation resistant to Class IA drugs."1.30ST segment elevation in the right precordial leads induced with class IC antiarrhythmic drugs: insight into the mechanism of Brugada syndrome. ( Fujiki, A; Hayashi, H; Inoue, H; Mizumaki, K; Nagasawa, H; Usui, M, 1999)
"Following flecainide administration, a ventricular tachycardia with close resemblance of the ECG morphology to sinus rhythm was induced."1.29Pleomorphic ventricular tachycardia with antegrade His-bundle activation: elucidation by multiple His-bundle recordings. ( Lee, KL; Tai, YT, 1994)
"The diagnosis of ventricular tachycardia is difficult, often requiring endocavitary investigation to obtain proof."1.29[Tachycardia with wide QRS. Limitations of electrocardiographic criteria in patients treated with anti-arrhythmia agents]. ( Dupuis, JM; Le Davay, M; Merheb, M; Tadeï, A; Tran, P; Victor, J, 1994)

Research

Studies (134)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's26 (19.40)18.2507
2000's17 (12.69)29.6817
2010's62 (46.27)24.3611
2020's29 (21.64)2.80

Authors

AuthorsStudies
Rolland, T1
Badenco, N1
Maupain, C1
Duthoit, G1
Waintraub, X1
Laredo, M1
Himbert, C1
Frank, R1
Hidden-Lucet, F1
Gandjbakhch, E2
Liu, JS1
Fan, EH1
Salvage, SC2
Habib, ZF1
Matthews, HR1
Jackson, AP1
Huang, CL3
Bannister, ML3
MacLeod, KT3
George, CH3
Ormerod, JOM1
Ormondroyd, E1
Li, Y1
Taylor, J1
Wei, J1
Guo, W1
Wang, R1
Sarton, CNS1
McGuire, K1
Dreau, HMP1
Taylor, JC1
Ginks, MR1
Rajappan, K1
Chen, SRW1
Watkins, H1
Ünal Yüksekgönül, A1
Azak, E1
Akalın, A1
Ertuğrul, İ1
Kılıç, E1
Utine, GE1
Karagöz, T1
Fraser, JA1
Dulhunty, AF1
Escande, W1
Gourraud, JB1
Haissaguerre, M2
Lavergne, T1
Martins, R1
Cheniti, G1
Krisai, P1
Hermida, JS1
Maury, P1
Merino, JL1
Pasquié, JL2
Combes, N1
Surget, E1
Duchateau, J1
Pambrun, T1
Derval, N1
Hocini, M1
Jaïs, P1
Postema, PG1
Nademanee, K1
Vigmond, E1
Bernus, O1
Sacher, F2
Probst, V1
Ryan, K1
Benz, P1
Zosel, A1
Farkas, A1
Theobald, J1
William, J1
Xiao, X1
Shirwaiker, A1
Patel, H1
Prabhu, S1
Ling, LH1
Sugamar, H1
Mariani, J1
Kistler, P1
Voskoboinik, A1
Kiani, S1
Sayegh, MN1
Ibrahim, R1
Bhatia, NK1
Merchant, FM1
Shah, AD1
Westerman, SB1
De Lurgio, DB1
Patel, AM1
Thompkins, CM1
Leon, AR1
Lloyd, MS1
El-Chami, MF1
Basza, M1
Maciejewski, C1
Bojanowicz, W1
Balsam, P1
Grabowski, M1
Mitkowski, P1
Kempa, M1
Kowalski, O1
Kalarus, Z1
Jaguszewski, M1
Lubiński, A1
Daniłowicz-Szymanowicz, L1
Szumowski, Ł1
Sterliński, M1
Kołtowski, Ł1
Przybylski, R1
Abrams, DJ1
Ebrahim, MA1
Alkhabbaz, AA1
Albash, B1
AlSayegh, AH1
Webster, G1
Kallas, D1
Roberts, JD1
Sanatani, S4
Roston, TM4
Sleiman, Y1
Reiken, S1
Charrabi, A1
Jaffré, F1
Sittenfeld, LR1
Colombani, S1
Lerman, BB1
Chen, S1
Marks, AR1
Cheung, JW1
Evans, T1
Lacampagne, A1
Meli, AC1
Davidson, R1
Medeiros, M1
Wang, G1
Zhao, N1
Zhong, S1
Wang, Y1
Li, J1
Nozaki, Y1
Kato, Y1
Uike, K1
Yamamura, K1
Kikuchi, M1
Yasuda, M1
Ohno, S2
Horie, M3
Murayama, T1
Kurebayashi, N1
Horigome, H1
Bensussan, H1
Mhamdi, K1
Kohli, U2
Aziz, Z2
Beaser, AD2
Nayak, HM2
Newson, JM1
Santos, CD1
Walters, BL1
Todd, BR1
Wagner, J1
Fitzpatrick, J1
Goldschlager, N1
Haanschoten, DM1
Vernooy, K1
Beukema, RJ1
Szili-Torok, T1
Ter Bekke, RMA1
Khan, M1
de Jong, JSSG1
Otten, AM1
Adiyaman, A1
Smit, JJJ1
Delnoy, PPHM1
Ramdat Misier, AR1
Elvan, A1
Rujirachun, P1
Junyavoraluk, A1
Pithukpakorn, M1
Suktitipat, B1
Winijkul, A1
Schumer, A1
Contag, S1
Donthi, N1
Chandrabhatla, T1
Genovese, L1
deFilippi, C1
Bertels, RA1
Kammeraad, JAE1
Zeelenberg, AM1
Filippini, LH1
Knobbe, I1
Kuipers, IM1
Blom, NA2
Benitah, JP1
Gómez, AM1
Tanaka, TD1
Suzuki, T1
Marcus, FI1
Kannankeril, PJ3
Moore, JP1
Cerrone, M1
Priori, SG5
Kertesz, NJ1
Ro, PS1
Batra, AS1
Kaufman, ES1
Fairbrother, DL1
Saarel, EV1
Etheridge, SP1
Kanter, RJ1
Carboni, MP1
Dzurik, MV1
Fountain, D1
Chen, H1
Ely, EW1
Roden, DM2
Knollmann, BC7
Poli, S1
Toniolo, M1
Maiani, M1
Zanuttini, D1
Rebellato, L1
Vendramin, I1
Dametto, E1
Bernardi, G1
Bassi, F1
Napolitano, C5
Livi, U1
Proclemer, A1
Aksu, T1
Güler, TE1
Özcan, KS1
Bozyel, S1
Yalın, K1
Wangüemert Pérez, F1
Hernández Afonso, JS1
Groba Marco, MDV1
Caballero Dorta, E1
Álvarez Acosta, L1
Campuzano Larrea, O1
Pérez, G1
Brugada Terradellas, J1
Brugada Terradellas, R1
Watts, TE1
McElderry, HT1
Kay, GN1
Evans, WN1
Acherman, RJ1
Law, IH1
Von Bergen, NH1
Samson, RA1
Restrepo, H1
Vaksmann, G1
Klug, D1
Friberg, L1
Pflaumer, A1
Davis, AM1
Ergül, Y1
Özgür, S1
Onan, SH1
Tuzcu, V1
Banavalikar, B1
Shenthar, J1
Padmanabhan, D1
Bucklew, EA1
Reis, SE1
Kancharla, K1
Wilgenhof, A1
Michiels, V1
Cosyns, B1
Courand, PY1
Sibellas, F1
Ranc, S1
Mullier, A1
Kirkorian, G1
Bonnefoy, E1
Lee, JY1
Lucchesi, BR1
Khoury, A1
Marai, I1
Suleiman, M1
Blich, M1
Lorber, A1
Gepstein, L1
Boulos, M1
Gopinathannair, R1
Ermakov, S1
Hoffmayer, KS1
Gerstenfeld, EP1
Scheinman, MM1
Mantziari, L1
Vassilikos, V1
Anastasakis, A1
Kotsaka, X1
Paraskevaidis, S1
Styliadis, IH1
Luria, D2
Osadchii, OE2
Massin, M1
Ould, AF1
Jacquemart, C1
Damry, N1
Wangüemert-Pérez, F1
Ruiz-Hernández, PM1
Campuzano, O1
Caballero-Dorta, E1
Bosch, C1
Brugada, J2
Brugada, R1
Kwan, D1
Vohra, R1
Dyer, JE1
Dornhoffer, P1
Miyamoto, K1
Aiba, T1
Kimura, H1
Hayashi, H3
Yasuoka, C1
Tanioka, Y1
Tsuchiya, T1
Yoshida, Y1
Tsuboi, I1
Nakajima, I1
Ishibashi, K1
Okamura, H1
Noda, T1
Ishihara, M1
Anzai, T1
Yasuda, S1
Miyamoto, Y1
Kamakura, S1
Kusano, K1
Ogawa, H1
Shimizu, W2
Thomas, NL2
Sikkel, MB2
Mukherjee, S2
Maxwell, C2
Williams, AJ2
Smith, GL1
MacQuaide, N1
Tsai, WC1
Lu, YY1
Chen, YC1
Chang, CJ1
Kao, YH1
Lin, YK1
Chen, YH1
Chen, SA1
Yang, LY1
Chen, YJ1
Kambiré, Y1
Konaté, L1
Millogo, GR1
Sib, E1
Amoussou, M1
Nebié, LV1
Niakara, A1
Jiménez-Jáimez, J1
Peinado, R1
Grima, EZ1
Segura, F1
Moriña, P1
Sánchez Muñoz, JJ1
Mazuelos, F1
Cózar, R1
Gimeno, JR1
Heras, RP1
Monserrat, L1
Domingo, D1
Ortiz-Genga, M1
Fernández Pastor, J1
Álvarez, M1
Tercedor, L1
Pappone, C1
Berruezo, A1
Vicedomini, G1
Manguso, F1
Ciconte, G1
Giannelli, L1
Santinelli, V1
Padfield, GJ1
AlAhmari, L1
Lieve, KV1
AlAhmari, T1
Wilde, AA8
Krahn, AD2
Yang, PC1
Moreno, JD1
Miyake, CY1
Vaughn-Behrens, SB1
Jeng, MT1
Grandi, E1
Wehrens, XH1
Noskov, SY1
Clancy, CE1
Imberti, JF1
Underwood, K1
Mazzanti, A1
Yu, TC1
Liu, AP1
Lun, KS1
Chung, BH1
Yung, TC1
Valentino, MA1
Panakos, A1
Ragupathi, L1
Williams, J1
Pavri, BB1
Preininger, MK1
Jha, R1
Maxwell, JT1
Wu, Q1
Singh, M1
Wang, B1
Dalal, A1
Mceachin, ZT1
Rossoll, W1
Hales, CM1
Fischbach, PS1
Wagner, MB1
Xu, C1
Bacic, D1
Carneiro, JS1
Bento, AA1
Nearing, BD1
Rajamani, S1
Belardinelli, L1
Verrier, RL1
Van Petegem, F1
Cunningham, TC1
Yavari, A1
Fryer, J1
Walker, DM1
Watanabe, H4
Chopra, N1
Laver, D2
Hwang, HS2
Davies, SS1
Roach, DE1
Duff, HJ1
Walker, NL1
Cobbe, SM1
McGavigan, AD1
Simpson, JM1
Maxwell, D1
Rosenthal, E1
Gill, H1
Letsas, KP1
Weber, R1
Astheimer, K1
Kalusche, D1
Arentz, T1
Lu, HR1
Rohrbacher, J1
Vlaminckx, E1
Van Ammel, K1
Yan, GX1
Gallacher, DJ1
Biernacka, EK1
Hoffman, P1
van der Werf, C3
Barajas-Martinez, H1
Hu, D1
Ontiveros, G1
Caceres, G1
Desai, M1
Burashnikov, E1
Scaglione, J1
Antzelevitch, C2
Soltysinska, E1
Olesen, SP1
Hasdemir, C1
Mehra, D1
Turhan, K1
Faggioni, M1
Yin, H2
Pott, C1
Dechering, DG1
Reinke, F1
Muszynski, A1
Zellerhoff, S1
Bittner, A1
Köbe, J1
Wasmer, K1
Schulze-Bahr, E1
Mönnig, G1
Kotthoff, S1
Eckardt, L1
Martin, CA1
Guzadhur, L1
Grace, AA1
Lei, M1
Viskin, S3
Leenhardt, A2
Sumitomo, N2
Fish, FA1
Bhuiyan, ZA3
Willems, AR1
van der Veen, MJ1
Laborderie, J1
Liu, N2
Denegri, M1
Ruan, Y1
Avelino-Cruz, JE1
Perissi, A1
Negri, S1
Coetzee, WA1
Boyden, PA1
Nof, E1
Belhassen, B1
Arad, M1
Rosso, R2
Fogelman, R1
El-Ani, D1
Mannens, MM1
Eldar, M1
Glikson, M1
Galimberti, ES1
Steele, DS1
Hong, RA1
Rivera, KK1
Jittirat, A1
Choi, JJ1
Venetucci, LA1
Denjoy, I1
Guicheney, P1
Roses-Noguer, F1
Adler, A1
Veltmann, C1
Bikker, H1
Minamino, T1
Till, J1
Apostolakis, S1
Oeff, M1
Tebbe, U1
Fabritz, L1
Breithardt, G1
Kirchhof, P1
D'Souza, D1
MacKenzie, WE1
Martin, WL1
Gasparini, M1
Mantica, M1
Galimberti, P1
Ceriotti, C1
Simonini, S1
Ackland, F1
Singh, R1
Thayyil, S1
Tukkie, R1
Sogaard, P1
Vleugels, J1
de Groot, IK1
Tan, HL1
Kanemoto, M1
Shimizu, A1
Yamagata, T1
Esato, M1
Ueyama, T1
Yoshiga, Y1
Kakugawa, H1
Kametani, R1
Inoue, N1
Sawa, A1
Matsuzaki, M1
Haghjoo, M1
Arya, A1
Emkanjoo, Z1
Sadr-Ameli, MA1
Rienstra, M1
Wiesfeld, AC1
van Veldhuisen, DJ1
van Gelder, IC1
Bökenkamp, R1
Schalij, MJ1
Mykytsey, A1
Bauman, JL1
Razminia, M1
Zheutlin, T1
Wang, T1
Saleem, M1
Leal, S1
Kehoe, RF1
Pellizzón, OA1
Kalaizich, L1
Ptácek, LJ1
Tristani-Firouzi, M1
Gonzalez, MD1
Stramba-Badiale, M1
Lazzarotti, M1
Facchini, M1
Schwartz, PJ1
Ranger, S1
Nattel, S1
Jung, W1
Mletzko, R1
Manz, M1
Nitsch, J1
Lüderitz, B1
Coromilas, J1
Saltman, AE1
Waldecker, B1
Dillon, SM1
Wit, AL1
Salerno, DM1
Murakami, MM1
Johnston, RB1
Keyler, DE1
Pentel, PR1
Restivo, M1
Caref, EB1
Patel, AI1
Ndrepepa, G1
Avitable, MJ1
Assadi, MA1
Isber, N1
el-Sherif, N1
Falk, RH1
Fogel, RI1
Fenrich, AL1
Perry, JC1
Friedman, RA1
Connaughton, M1
Jenkins, BS1
Tai, YT1
Lee, KL1
Le Davay, M1
Victor, J1
Dupuis, JM1
Merheb, M1
Tran, P1
Tadeï, A1
Said, SA1
Somer, ST1
Oude Luttikhuis, HA1
Ismail, Z1
Alwi, M1
Lim, MK1
Murtazam, HA1
Jamaluddin, A1
Gutiérrez-Larraya, F1
Jabón, A1
Ogawa, S1
Mitamura, H1
Katoh, H1
Tisdale, JE1
Kluger, J1
Fisher, JR1
Chow, MS1
Kidwell, GA1
Greenspon, AJ1
Greenberg, RM1
Volosin, KJ1
van Hemel, NM1
Kingma, JH1
Defauw, JJ1
Hoogteijling-van Dusseldorp, E1
Kelder, JC1
Beukema, WP1
Vermeulen, FE1
De Micheli, A1
Medrano, GA1
Iturralde, P1
Casanova, JM1
Hanley, NA1
Bourke, JP1
Gascoigne, AD1
Nakamura, W1
Segawa, K1
Ito, H1
Tanaka, S1
Yoshimoto, N1
Fujiki, A1
Usui, M1
Nagasawa, H1
Mizumaki, K1
Inoue, H1
Swan, H1
Piippo, K1
Viitasalo, M1
Heikkilä, P1
Paavonen, T1
Kainulainen, K1
Kere, J1
Keto, P1
Kontula, K1
Toivonen, L1
Chalvidan, T1
Cellarier, G1
Deharo, JC1
Colin, R1
Savon, N1
Barra, N1
Peyre, JP1
Djiane, P1
Watanabe, T1
Yamaki, M1
Tachibana, H1
Yamauchi, S1
Kubota, I1
Tomoike, H1
Yasui, K1
Shibata, T1
Yokoyama, U1
Nishizawa, T1
Takigiku, K1
Sakon, T1
Kobayashi, H1
Iwamoto, M1
Niimura, I1
Lombardi, F1
Torzillo, D1
Sandrone, G1
Dalla Vecchia, L1
Cappiello, E1
Gill, JS1
Mehta, D1
Ward, DE1
Camm, AJ1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Prospective Randomized Crossover Trial of Oral Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia[NCT01117454]14 participants (Actual)Interventional2011-12-31Completed
Electrical Substrate Elimination in Brugada Syndrome. Results in 135 Consecutive Patients[NCT02641431]135 participants (Actual)Interventional2015-11-16Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Patients With Ventricular Ectopy or VT During Exercise Treadmill Testing

Hypothesis: the addition of oral flecainide to standard therapy will reduce ventricular ectopy and/or VT on treadmill exercise treadmill testing in patients with CPVT, compared to placebo plus standard therapy. (NCT01117454)
Timeframe: 3 months

InterventionParticipants (Count of Participants)
Flecainide2
Placebo9

Reviews

22 reviews available for flecainide and Tachycardia, Ventricular

ArticleYear
Ca2+-dependent modulation of voltage-gated myocyte sodium channels.
    Biochemical Society transactions, 2021, 11-01, Volume: 49, Issue:5

    Topics: Action Potentials; Animals; Binding Sites; Calcium; Calcium Signaling; Disease Models, Animal; Fleca

2021
Moving in the right direction: elucidating the mechanisms of interaction between flecainide and the cardiac ryanodine receptor.
    British journal of pharmacology, 2022, Volume: 179, Issue:11

    Topics: Anti-Arrhythmia Agents; Calcium; Flecainide; Humans; Mutation; Myocytes, Cardiac; Ryanodine Receptor

2022
Malignant Purkinje ectopy induced by sodium channel blockers.
    Heart rhythm, 2022, Volume: 19, Issue:10

    Topics: Adult; Ajmaline; Catheter Ablation; Electrocardiography; Flecainide; Humans; Male; Middle Aged; Repr

2022
Flecainide in clinical practice.
    Cardiology journal, 2023, Volume: 30, Issue:3

    Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Child; Female; Flecainide; Humans; Pregnancy; Propafeno

2023
Current management of inherited arrhythmia syndromes associated with the cardiac ryanodine receptor.
    Current opinion in cardiology, 2023, 07-01, Volume: 38, Issue:4

    Topics: Adrenergic beta-Antagonists; Flecainide; Humans; Mutation; Nadolol; Ryanodine Receptor Calcium Relea

2023
Calcium Release Deficiency Syndrome: A New Inherited Arrhythmia Syndrome.
    Cardiac electrophysiology clinics, 2023, Volume: 15, Issue:3

    Topics: Calcium; Electrocardiography; Flecainide; Humans; Mutation; Ryanodine Receptor Calcium Release Chann

2023
Safety and efficacy of flecainide for patients with catecholaminergic polymorphic ventricular tachycardia: A systematic review and meta-analysis.
    Medicine, 2019, Volume: 98, Issue:34

    Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Female; Flecainide; Humans; Male; Randomized Co

2019
[Flecainid intoxication: Evolution, complications and care of].
    Annales de cardiologie et d'angeiologie, 2020, Volume: 69, Issue:2

    Topics: Anti-Arrhythmia Agents; Asperger Syndrome; Flecainide; Humans; Length of Stay; Male; Suicide, Attemp

2020
Successful treatment of arrhythmia with β-blocker and flecainide combination in pregnant patients with Andersen-Tawil syndrome: A case report and literature review.
    Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc, 2021, Volume: 26, Issue:3

    Topics: Adrenergic beta-Antagonists; Adult; Andersen Syndrome; Anti-Arrhythmia Agents; Female; Flecainide; H

2021
Management of untreatable ventricular arrhythmias during pharmacologic challenges with sodium channel blockers for suspected Brugada syndrome.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2018, 02-01, Volume: 20, Issue:2

    Topics: Action Potentials; Adolescent; Adult; Aged; Aged, 80 and over; Ajmaline; Brugada Syndrome; Cardiopul

2018
An Update on the Diagnosis and Management of Catecholaminergic Polymorphic Ventricular Tachycardia.
    Heart, lung & circulation, 2019, Volume: 28, Issue:3

    Topics: Adrenergic beta-Antagonists; Calsequestrin; Defibrillators, Implantable; Flecainide; Humans; Mutatio

2019
Clinical Challenges in Catecholaminergic Polymorphic Ventricular Tachycardia.
    Heart, lung & circulation, 2016, Volume: 25, Issue:8

    Topics: Female; Flecainide; Humans; Male; Prevalence; Sympathectomy; Tachycardia, Ventricular

2016
Flecainide Toxicity: A Case Report and Systematic Review of its Electrocardiographic Patterns and Management.
    Cardiovascular toxicology, 2017, Volume: 17, Issue:3

    Topics: Anti-Arrhythmia Agents; Disease Management; Electrocardiography; Flecainide; Humans; Male; Middle Ag

2017
Catecholaminergic polymorphic ventricular tachycardia: a model for genotype-specific therapy.
    Current opinion in cardiology, 2017, Volume: 32, Issue:1

    Topics: Animals; Anti-Arrhythmia Agents; Defibrillators, Implantable; Flecainide; Genetic Therapy; Genotype;

2017
Advances in the diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia.
    Cardiology in the young, 2017, Volume: 27, Issue:S1

    Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implant

2017
Fetal ventricular tachycardia secondary to long QT syndrome treated with maternal intravenous magnesium: case report and review of the literature.
    Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, 2009, Volume: 34, Issue:4

    Topics: Adult; Anti-Arrhythmia Agents; Female; Fetal Diseases; Flecainide; Humans; Injections, Intravenous;

2009
Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2011, Volume: 13, Issue:6

    Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Calcium Channel Blockers; Child; Death, Sudden,

2011
Flecainide and antiarrhythmic effects in a mouse model of catecholaminergic polymorphic ventricular tachycardia.
    Trends in cardiovascular medicine, 2012, Volume: 22, Issue:2

    Topics: Animals; Anti-Arrhythmia Agents; Catecholamines; Disease Models, Animal; Flecainide; Mice; Myocytes,

2012
Catecholaminergic polymorphic ventricular tachycardia.
    Circulation. Arrhythmia and electrophysiology, 2012, Volume: 5, Issue:5

    Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Calsequestrin; Defibrillators, Implant

2012
Flecainide acetate for the treatment of atrial and ventricular arrhythmias.
    Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:3

    Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Flecainide; Humans; Prac

2013
Flecainide.
    Journal of cardiovascular electrophysiology, 1994, Volume: 5, Issue:11

    Topics: Atrial Fibrillation; Electrocardiography; Flecainide; Heart; Hemodynamics; Humans; Tachycardia, Vent

1994
[Tachycardias: considerations in childhood in the 90s].
    Anales espanoles de pediatria, 1993, Volume: 39, Issue:6

    Topics: Adenosine; Adolescent; Adult; Amiodarone; Atrial Flutter; Child; Child, Preschool; Electrocardiograp

1993

Trials

7 trials available for flecainide and Tachycardia, Ventricular

ArticleYear
Elimination of Benign Ventricular Premature Beats or Ventricular Tachycardia with Catheter Ablation versus Two Different Optimal Antiarrhythmic Drug Treatment Regimens (Sotalol or Verapamil/Flecainide).
    Cardiology, 2020, Volume: 145, Issue:12

    Topics: Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Catheter Ablation; Flecainide; Humans; Prospec

2020
Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial.
    JAMA cardiology, 2017, 07-01, Volume: 2, Issue:7

    Topics: Adolescent; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Cross-Over Studies; Death, Sudden,

2017
Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
    Heart rhythm, 2013, Volume: 10, Issue:11

    Topics: Adolescent; Anti-Arrhythmia Agents; Calsequestrin; Death, Sudden, Cardiac; DNA; Electrocardiography;

2013
Efficacy and safety of flecainide for ventricular arrhythmias in patients with Andersen-Tawil syndrome with KCNJ2 mutations.
    Heart rhythm, 2015, Volume: 12, Issue:3

    Topics: Administration, Oral; Adolescent; Adult; Andersen Syndrome; Anti-Arrhythmia Agents; Electrocardiogra

2015
Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function.
    Journal of cardiovascular pharmacology and therapeutics, 2007, Volume: 12, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut

2007
Continuation of antiarrhythmic drugs, or arrhythmia surgery after multiple drug failures. A randomized trial in the treatment of postinfarction ventricular tachycardia.
    European heart journal, 1996, Volume: 17, Issue:4

    Topics: Adult; Aged; Anti-Arrhythmia Agents; Female; Flecainide; Humans; Male; Middle Aged; Propafenone; Sot

1996
A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Antiarrhythmic Drug Evaluation Group (A.D.E.G.).
    European heart journal, 1992, Volume: 13, Issue:9

    Topics: Amiodarone; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic; Dose-Response Relationship, Drug;

1992

Other Studies

105 other studies available for flecainide and Tachycardia, Ventricular

ArticleYear
Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2022, 02-02, Volume: 24, Issue:2

    Topics: Arrhythmogenic Right Ventricular Dysplasia; Atrial Fibrillation; Defibrillators, Implantable; Flecai

2022
Toxic Effects of Flecainide in a Patient With Kidney Failure and Tachyarrhythmia.
    JAMA internal medicine, 2021, 11-01, Volume: 181, Issue:11

    Topics: Aged; Atrial Flutter; Diagnosis, Differential; Dose-Response Relationship, Drug; Female; Flecainide;

2021
Provocation Testing and Therapeutic Response in a Newly Described Channelopathy: RyR2 Calcium Release Deficiency Syndrome.
    Circulation. Genomic and precision medicine, 2022, Volume: 15, Issue:1

    Topics: Animals; Arrhythmias, Cardiac; Calcium; Channelopathies; Death, Sudden, Cardiac; Flecainide; Humans;

2022
Efficacy of flecainide in bidirectional ventricular tachycardia and tachycardia-induced cardiomyopathy with Andersen-Tawil syndrome.
    European journal of medical genetics, 2022, Volume: 65, Issue:6

    Topics: Adolescent; Andersen Syndrome; Cardiomyopathies; Child; Female; Flecainide; Humans; Tachycardia; Tac

2022
How does flecainide impact RyR2 channel function?
    The Journal of general physiology, 2022, 09-05, Volume: 154, Issue:9

    Topics: Anti-Arrhythmia Agents; Calcium; Flecainide; Humans; Myocytes, Cardiac; Ryanodine; Ryanodine Recepto

2022
QTc Prolongation in Poison Center Exposures to CredibleMeds List of Substances with "Known Risk of Torsades de Pointes".
    Cardiovascular toxicology, 2022, Volume: 22, Issue:9

    Topics: Amitriptyline; Arrhythmias, Cardiac; Diphenhydramine; Electrocardiography; Flecainide; Humans; Long

2022
Diagnostic evaluation of unexplained ventricular tachyarrhythmias in younger adults.
    Journal of cardiovascular electrophysiology, 2023, Volume: 34, Issue:4

    Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Flecainide; Heart Arrest; Humans; Retro

2023
The Feasibility and Safety of Flecainide Use Among Patients With Varying Degrees of Coronary Disease.
    JACC. Clinical electrophysiology, 2023, Volume: 9, Issue:7 Pt 2

    Topics: Coronary Artery Disease; Feasibility Studies; Flecainide; Humans; Retrospective Studies; Sotalol; Ta

2023
Trans-2,3-enoyl-CoA reductase-like-related catecholaminergic polymorphic ventricular tachycardia with regular ventricular tachycardia and response to flecainide.
    Journal of cardiovascular electrophysiology, 2023, Volume: 34, Issue:9

    Topics: Anti-Arrhythmia Agents; Flecainide; Humans; Oxidoreductases; Ryanodine Receptor Calcium Release Chan

2023
Personalized medicine in the dish to prevent calcium leak associated with short-coupled polymorphic ventricular tachycardia in patient-derived cardiomyocytes.
    Stem cell research & therapy, 2023, 09-23, Volume: 14, Issue:1

    Topics: Anti-Arrhythmia Agents; Calcium; Flecainide; Humans; Myocytes, Cardiac; Precision Medicine; Proprano

2023
Insights on the mechanism of flecainide in catecholaminergic polymorphic ventricular tachycardia.
    Journal of medicine and life, 2023, Volume: 16, Issue:8

    Topics: Anti-Arrhythmia Agents; Calcium; Flecainide; Humans; Mutation; Ryanodine Receptor Calcium Release Ch

2023
Co-Phenotype of Left Ventricular Non-Compaction Cardiomyopathy and Atypical Catecholaminergic Polymorphic Ventricular Tachycardia in Association With R169Q, a Ryanodine Receptor Type 2 Missense Mutation.
    Circulation journal : official journal of the Japanese Circulation Society, 2020, 01-24, Volume: 84, Issue:2

    Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Calcium Signaling; Child; Child, Preschool; Dea

2020
Ventricular arrhythmia suppression with ivabradine in a patient with catecholaminergic polymorphic ventricular tachycardia refractory to nadolol, flecainide, and sympathectomy.
    Pacing and clinical electrophysiology : PACE, 2020, Volume: 43, Issue:5

    Topics: Adolescent; Cardiovascular Agents; Electrocardiography; Exercise Test; Flecainide; Humans; Ivabradin

2020
The Case of Flecainide Toxicity: What to Look for and How to Treat.
    The Journal of emergency medicine, 2020, Volume: 59, Issue:2

    Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Flecainide; Humans; Middle

2020
VT or Not VT?: That Is the Question.
    Circulation, 2020, 08-11, Volume: 142, Issue:6

    Topics: Aged; Anti-Arrhythmia Agents; Atrial Flutter; Drug-Related Side Effects and Adverse Reactions; Elect

2020
Catecholaminergic polymorphic ventricular tachycardia in pregnancy: a case report.
    Journal of medical case reports, 2020, Dec-09, Volume: 14, Issue:1

    Topics: Death, Sudden, Cardiac; Female; Flecainide; Humans; Pregnancy; Ryanodine Receptor Calcium Release Ch

2020
Fast and furious: flecainide toxicity presenting as monomorphic ventricular tachycardia.
    BMJ case reports, 2020, Dec-13, Volume: 13, Issue:12

    Topics: Amiodarone; Electrocardiography; Female; Flecainide; Humans; Middle Aged; Tachycardia, Ventricular;

2020
The Efficacy of Anti-Arrhythmic Drugs in Children With Idiopathic Frequent Symptomatic or Asymptomatic Premature Ventricular Complexes With or Without Asymptomatic Ventricular Tachycardia: a Retrospective Multi-Center Study.
    Pediatric cardiology, 2021, Volume: 42, Issue:4

    Topics: Adolescent; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Child; Child, Preschool; Female; Fl

2021
Is the Debate on the Flecainide Action on the RYR2 in CPVT Closed?
    Circulation research, 2021, 02-05, Volume: 128, Issue:3

    Topics: Anti-Arrhythmia Agents; Flecainide; Humans; Ryanodine Receptor Calcium Release Channel; Tachycardia,

2021
Sustained Wide Complex Tachycardia in a Healthy Man.
    JAMA internal medicine, 2021, 10-01, Volume: 181, Issue:10

    Topics: Adult; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Bisoprolol; Defibrillator

2021
Renal sympathetic denervation assisted treatment of electrical storm due to polymorphic ventricular tachycardia in a patient with cathecolaminergic polymorphic ventricular tachycardia.
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2017, Volume: 45, Issue:5

    Topics: Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Atenolol; Catheter Ablation; Electrocard

2017
Flecainide Reduces Ventricular Arrhythmias in Patients With Genotype RyR2-positive Catecholaminergic Polymorphic Ventricular Tachycardia.
    Revista espanola de cardiologia (English ed.), 2018, Volume: 71, Issue:3

    Topics: Adult; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; DNA Mutational Analysis; Electrocardiography;

2018
An Irregular Wide Complex Tachycardia.
    Circulation, 2017, 08-22, Volume: 136, Issue:8

    Topics: Action Potentials; Administration, Intravenous; Aged; Anti-Arrhythmia Agents; Electrocardiography; F

2017
Neonatal complex arrhythmias possibly related to a TTN mutation.
    Journal of neonatal-perinatal medicine, 2017, Volume: 10, Issue:3

    Topics: Amiodarone; Anti-Arrhythmia Agents; Bundle-Branch Block; Connectin; Electrocardiography; Fetal Monit

2017
Efficacy of ivabradine to control ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia.
    Pacing and clinical electrophysiology : PACE, 2018, Volume: 41, Issue:10

    Topics: Adolescent; Anti-Arrhythmia Agents; Cardiovascular Agents; Electrocardiography; Exercise Test; Femal

2018
Ventricular arrhythmia and death among atrial fibrillation patients using anti-arrhythmic drugs.
    American heart journal, 2018, Volume: 205

    Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cause of Death; Dronedarone; Female; Flecainide;

2018
Can flecainide totally eliminate bidirectional ventricular tachycardia in pediatric patients with Andersen-Tawil syndrome?
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2018, Volume: 46, Issue:8

    Topics: Adolescent; Andersen Syndrome; Anti-Arrhythmia Agents; Child; Female; Flecainide; Humans; Tachycardi

2018
Unusual Wide Complex Tachycardia During Rhythm Control for Atrial Fibrillation.
    Circulation, 2018, 07-31, Volume: 138, Issue:5

    Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Flecainide; Heart Ra

2018
Wide QRS Tachycardia in a Man With a Medical History of Atrial Fibrillation.
    JAMA internal medicine, 2019, 04-01, Volume: 179, Issue:4

    Topics: Aged; Atrial Fibrillation; Catheter Ablation; Electrocardiography; Flecainide; Heart Conduction Syst

2019
A large deletion in RYR2 exon 3 is associated with nadolol and flecainide refractory catecholaminergic polymorphic ventricular tachycardia.
    Pacing and clinical electrophysiology : PACE, 2019, Volume: 42, Issue:8

    Topics: Adolescent; Anti-Arrhythmia Agents; Exons; Flecainide; Gene Deletion; Humans; Male; Nadolol; Ryanodi

2019
An irregular, extremely broad QRS complex rhythm.
    The American journal of emergency medicine, 2019, Volume: 37, Issue:10

    Topics: Accidental Falls; Aged; Anti-Arrhythmia Agents; Drug Overdose; Electrocardiography; Fatigue; Female;

2019
Arrhythmogenic effect of flecainide toxicity.
    Cardiology journal, 2013, Volume: 20, Issue:2

    Topics: Adenosine Triphosphate; Aged; Anti-Arrhythmia Agents; Bundle-Branch Block; Electrocardiography; Fema

2013
HBI-3000 prevents secondary sudden cardiac death.
    Journal of cardiovascular pharmacology and therapeutics, 2013, Volume: 18, Issue:5

    Topics: Animals; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Disease Models, Animal; Dogs; Dose-Response

2013
Flecainide in CASQ2-mediated catecholaminergic polymorphic ventricular tachycardia: the gift that keeps on giving.
    Heart rhythm, 2013, Volume: 10, Issue:11

    Topics: Calsequestrin; Death, Sudden, Cardiac; Exercise Test; Female; Flecainide; Humans; Male; Tachycardia,

2013
Combination drug therapy for patients with intractable ventricular tachycardia associated with right ventricular cardiomyopathy.
    Pacing and clinical electrophysiology : PACE, 2014, Volume: 37, Issue:1

    Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Chronic Disease; Dr

2014
A de novo novel cardiac ryanodine mutation (Ser4155Tyr) associated with catecholaminergic polymorphic ventricular tachycardia.
    Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc, 2013, Volume: 18, Issue:6

    Topics: Adolescent; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Flecainide; Follow-Up Studi

2013
Effects of Na+ channel blockers on extrasystolic stimulation-evoked changes in ventricular conduction and repolarization.
    Journal of cardiovascular pharmacology, 2014, Volume: 63, Issue:3

    Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrophysiological Pheno

2014
Long-term conservative management of a giant cardiac fibroma.
    Acta cardiologica, 2013, Volume: 68, Issue:5

    Topics: Anti-Arrhythmia Agents; Disease Progression; Echocardiography; Female; Fibroma; Flecainide; Follow-U

2013
Flecainide in patient with aggressive catecholaminergic polymorphic ventricular tachycardia due to novel RYR2 mutation.
    Minerva cardioangiologica, 2014, Volume: 62, Issue:4

    Topics: Adult; Anti-Arrhythmia Agents; Electrocardiography; Flecainide; Humans; Male; Mutation; Ryanodine Re

2014
An infant with a heartbreaking medication error.
    Pediatric emergency care, 2014, Volume: 30, Issue:12

    Topics: Drug Overdose; Extracorporeal Membrane Oxygenation; Flecainide; Humans; Infant; Male; Medication Err

2014
The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2.
    Circulation research, 2015, Apr-10, Volume: 116, Issue:8

    Topics: Animals; Anti-Arrhythmia Agents; Calcium Signaling; Dose-Response Relationship, Drug; Flecainide; HE

2015
The direct actions of flecainide on the human cardiac ryanodine receptor: keeping open the debate on the mechanism of action of local anesthetics in CPVT.
    Circulation research, 2015, Apr-10, Volume: 116, Issue:8

    Topics: Animals; Anti-Arrhythmia Agents; Flecainide; Humans; Male; Myocytes, Cardiac; Ryanodine Receptor Cal

2015
Ablation of androgen receptor gene triggers right ventricular outflow tract ventricular tachycardia.
    International journal of cardiology, 2015, Jun-15, Volume: 189

    Topics: Action Potentials; Adenosine; Animals; Caffeine; Calcium; Flecainide; Gene Knockdown Techniques; Gen

2015
Right ventricular outflow tract tachycardia worsened during pregnancy.
    The Pan African medical journal, 2015, Volume: 20

    Topics: Adult; Anti-Arrhythmia Agents; Catheter Ablation; Drug Therapy, Combination; Female; Flecainide; Hos

2015
Diagnostic Approach to Unexplained Cardiac Arrest (from the FIVI-Gen Study).
    The American journal of cardiology, 2015, Sep-15, Volume: 116, Issue:6

    Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Catheteri

2015
Brugada Syndrome Phenotype Elimination by Epicardial Substrate Ablation.
    Circulation. Arrhythmia and electrophysiology, 2015, Volume: 8, Issue:6

    Topics: Action Potentials; Adult; Anti-Arrhythmia Agents; Brugada Syndrome; Catheter Ablation; Death, Sudden

2015
Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of β-blockade.
    Heart rhythm, 2016, Volume: 13, Issue:2

    Topics: Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Drug M

2016
Flecainide monotherapy for catecholaminergic polymorphic ventricular tachycardia: Perspectives and limitations.
    Heart rhythm, 2016, Volume: 13, Issue:2

    Topics: Anti-Arrhythmia Agents; Flecainide; Humans; Tachycardia; Tachycardia, Ventricular

2016
In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia.
    The Journal of physiology, 2016, Feb-01, Volume: 594, Issue:3

    Topics: Animals; Animals, Genetically Modified; Anti-Arrhythmia Agents; Electrocardiography; Flecainide; Mic

2016
Clinical and genetic profile of catecholaminergic polymorphic ventricular tachycardia in Hong Kong Chinese children.
    Hong Kong medical journal = Xianggang yi xue za zhi, 2016, Volume: 22, Issue:4

    Topics: Adolescent; Child; Defibrillators, Implantable; Female; Flecainide; Humans; Male; Tachycardia, Ventr

2016
A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses.
    Disease models & mechanisms, 2016, 09-01, Volume: 9, Issue:9

    Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Biomarkers; Calcium; Calcium Signaling; Catechola

2016
Eleclazine, an inhibitor of the cardiac late sodium current, is superior to flecainide in suppressing catecholamine-induced ventricular tachycardia and T-wave alternans in an intact porcine model.
    Heart rhythm, 2017, Volume: 14, Issue:3

    Topics: Administration, Intravenous; Animals; Catecholamines; Disease Models, Animal; Drug Monitoring; Elect

2017
Questioning flecainide's mechanism of action in the treatment of catecholaminergic polymorphic ventricular tachycardia.
    The Journal of physiology, 2016, 11-01, Volume: 594, Issue:21

    Topics: Electrocardiography; Flecainide; Humans; Tachycardia, Ventricular

2016
A dangerous secret.
    The American journal of medicine, 2009, Volume: 122, Issue:2

    Topics: Adolescent; Anti-Arrhythmia Agents; Diagnosis, Differential; Drug Overdose; Electrocardiography; Fle

2009
Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans.
    Nature medicine, 2009, Volume: 15, Issue:4

    Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium; Child; Flecainide; Heart Rate; Human

2009
Paroxysmal bidirectional ventricular tachycardia with tachycardiomyopathy in a pregnant woman.
    Acta cardiologica, 2009, Volume: 64, Issue:3

    Topics: Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Bisoprolol; Cesarean Section; Female; Fl

2009
Tpeak-Tend interval and Tpeak-Tend/QT ratio as markers of ventricular tachycardia inducibility in subjects with Brugada ECG phenotype.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2010, Volume: 12, Issue:2

    Topics: Adult; Ajmaline; Anti-Arrhythmia Agents; Biomarkers; Brugada Syndrome; Electrocardiography; Female;

2010
Predicting drug-induced slowing of conduction and pro-arrhythmia: identifying the 'bad' sodium current blockers.
    British journal of pharmacology, 2010, Volume: 160, Issue:1

    Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; CHO Cells; Cricetinae; Cricetulus; Drug Evalu

2010
Efficacy of flecainide in a patient with catecholaminergic polymorphic ventricular tachycardia.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2011, Volume: 13, Issue:1

    Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Anti-Arrhythmia Agents; Bisoprolol; Dose-Response Rel

2011
Catecholaminergic polymorphic ventricular tachycardia: important messages from case reports.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2011, Volume: 13, Issue:1

    Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Catecholamin

2011
Biophysical and molecular characterization of a novel de novo KCNJ2 mutation associated with Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia mimicry.
    Circulation. Cardiovascular genetics, 2011, Volume: 4, Issue:1

    Topics: Amino Acid Sequence; Amino Acid Substitution; Andersen Syndrome; Arrhythmias, Cardiac; Base Sequence

2011
Na+ channel distribution and electrophysiological heterogeneities in guinea pig ventricular wall.
    American journal of physiology. Heart and circulatory physiology, 2011, Volume: 300, Issue:3

    Topics: Action Potentials; Animals; Electrocardiography; Flecainide; Guinea Pigs; Heart Conduction System; M

2011
Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
    Circulation. Arrhythmia and electrophysiology, 2011, Volume: 4, Issue:2

    Topics: Analysis of Variance; Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Calsequestrin; Defi

2011
Mapping of reentrant spontaneous polymorphic ventricular tachycardia in a Scn5a+/- mouse model.
    American journal of physiology. Heart and circulatory physiology, 2011, Volume: 300, Issue:5

    Topics: Animals; Anti-Arrhythmia Agents; Brugada Syndrome; Disease Models, Animal; Electrocardiography; Elec

2011
Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia.
    Journal of the American College of Cardiology, 2011, May-31, Volume: 57, Issue:22

    Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Child; Defibrillators, Implan

2011
Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity.
    Circulation research, 2011, Jul-22, Volume: 109, Issue:3

    Topics: Animals; Anti-Arrhythmia Agents; Calcium Signaling; Disease Models, Animal; Extracellular Space; Fle

2011
Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene.
    Heart rhythm, 2011, Volume: 8, Issue:10

    Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Catheter Ablation; Child; Dea

2011
Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin.
    Journal of molecular and cellular cardiology, 2011, Volume: 51, Issue:5

    Topics: Animals; Anti-Arrhythmia Agents; Calcium; Calcium Signaling; Calsequestrin; Cell Membrane Permeabili

2011
Mechanism of antiarrhythmic effects of flecainide in catecholaminergic polymorphic ventricular tachycardia.
    Circulation research, 2011, Sep-02, Volume: 109, Issue:6

    Topics: Animals; Anti-Arrhythmia Agents; Flecainide; Ryanodine Receptor Calcium Release Channel; Tachycardia

2011
Flecainide suppresses defibrillator-induced storming in catecholaminergic polymorphic ventricular tachycardia.
    Pacing and clinical electrophysiology : PACE, 2012, Volume: 35, Issue:7

    Topics: Adolescent; Anti-Arrhythmia Agents; Defibrillators, Implantable; Flecainide; Humans; Male; Tachycard

2012
Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.
    Heart rhythm, 2013, Volume: 10, Issue:4

    Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Child; Cohort Studies; Elect

2013
Transplacental flecainide therapy in the treatment of fetal supraventricular tachycardia.
    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2002, Volume: 22, Issue:3

    Topics: Adult; Anti-Arrhythmia Agents; Cardiotocography; Electrocardiography; Female; Fetal Diseases; Flecai

2002
Flecainide test in Brugada syndrome: a reproducible but risky tool.
    Pacing and clinical electrophysiology : PACE, 2003, Volume: 26, Issue:1P2

    Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Bundle-Branch Block; Death, Sudden, Cardiac; Electrocardi

2003
Flecainide induced ventricular fibrillation in a neonate.
    Heart (British Cardiac Society), 2003, Volume: 89, Issue:10

    Topics: Anti-Arrhythmia Agents; Fatal Outcome; Flecainide; Humans; Infant, Newborn; Tachycardia, Supraventri

2003
Delay in right ventricular activation contributes to Brugada syndrome.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Action Potentials; Adult; Anti-Arrhythmia Agents; Calcium Channels, L-Type; Echocardiography, Dopple

2004
Differentiation of the electrophysiological effects on the atrial myocardium between the pure Na channel blocker, pilsicainide, and flecainide.
    Cardiovascular drugs and therapy, 2004, Volume: 18, Issue:4

    Topics: Adult; Anti-Arrhythmia Agents; Atrial Flutter; Electrocardiography; Electrophysiologic Techniques, C

2004
Clinical and electrophysiologic profile of Brugada syndrome in Iranian patients.
    Asian cardiovascular & thoracic annals, 2005, Volume: 13, Issue:3

    Topics: Adult; Anti-Arrhythmia Agents; Bundle-Branch Block; Defibrillators, Implantable; Electric Stimulatio

2005
[Life-threatening ventricular tachycardia during flecainide treatment for symptomatic atrial fibrillation in a patient with a structural cardiac disorder].
    Nederlands tijdschrift voor geneeskunde, 2006, May-06, Volume: 150, Issue:18

    Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Flecainide; Humans; Male; T

2006
Flecainide for recurrent malignant ventricular arrhythmias in two siblings with Andersen-Tawil syndrome.
    Heart rhythm, 2007, Volume: 4, Issue:4

    Topics: Andersen Syndrome; Anti-Arrhythmia Agents; Child; Child, Preschool; Defibrillators, Implantable; Fem

2007
Flecainide suppresses bidirectional ventricular tachycardia and reverses tachycardia-induced cardiomyopathy in Andersen-Tawil syndrome.
    Journal of cardiovascular electrophysiology, 2008, Volume: 19, Issue:1

    Topics: Adolescent; Andersen Syndrome; Anti-Arrhythmia Agents; Cardiomyopathies; Female; Flecainide; Humans;

2008
Malignant arrhythmias and acute myocardial ischemia: interaction between flecainide and the autonomic nervous system.
    American heart journal, 1994, Volume: 128, Issue:5

    Topics: Animals; Autonomic Nervous System; Cardiac Complexes, Premature; Cats; Electrocardiography; Flecaini

1994
Determinants and mechanisms of flecainide-induced promotion of ventricular tachycardia in anesthetized dogs.
    Circulation, 1995, Sep-01, Volume: 92, Issue:5

    Topics: Animals; Cardiac Pacing, Artificial; Dogs; Dose-Response Relationship, Drug; Electrocardiography; Fl

1995
Efficacy and safety of combination therapy with amiodarone and type I agents for treatment of inducible ventricular tachycardia.
    Pacing and clinical electrophysiology : PACE, 1993, Volume: 16, Issue:4 Pt 1

    Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Drug Therapy, Combinati

1993
Electrophysiological effects of flecainide on anisotropic conduction and reentry in infarcted canine hearts.
    Circulation, 1995, Apr-15, Volume: 91, Issue:8

    Topics: Animals; Anisotropy; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Dogs; Electrocardiography; El

1995
Reversal of flecainide-induced ventricular arrhythmia by hypertonic sodium bicarbonate in dogs.
    The American journal of emergency medicine, 1995, Volume: 13, Issue:3

    Topics: Animals; Cardiac Pacing, Artificial; Disease Models, Animal; Dogs; Electrocardiography; Flecainide;

1995
Reentrant arrhythmias in the subacute infarction period. The proarrhythmic effect of flecainide acetate on functional reentrant circuits.
    Circulation, 1995, Feb-15, Volume: 91, Issue:4

    Topics: Animals; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Death, Sudden, Cardiac; Dogs; Electrocard

1995
Flecainide and amiodarone: combined therapy for refractory tachyarrhythmias in infancy.
    Journal of the American College of Cardiology, 1995, Volume: 25, Issue:5

    Topics: Amiodarone; Drug Therapy, Combination; Electrocardiography, Ambulatory; Female; Flecainide; Follow-U

1995
Successful use of flecainide to treat new onset maternal ventricular tachycardia in pregnancy.
    British heart journal, 1994, Volume: 72, Issue:3

    Topics: Adult; Electrocardiography; Female; Flecainide; Heart; Humans; Pregnancy; Pregnancy Complications, C

1994
Pleomorphic ventricular tachycardia with antegrade His-bundle activation: elucidation by multiple His-bundle recordings.
    Journal of cardiovascular electrophysiology, 1994, Volume: 5, Issue:4

    Topics: Anti-Arrhythmia Agents; Bundle of His; Cardiac Pacing, Artificial; Electrocardiography; Electrophysi

1994
[Tachycardia with wide QRS. Limitations of electrocardiographic criteria in patients treated with anti-arrhythmia agents].
    Annales de cardiologie et d'angeiologie, 1994, Volume: 43, Issue:5

    Topics: Anti-Arrhythmia Agents; Diagnosis, Differential; Electrocardiography; Flecainide; Humans; Male; Midd

1994
Flecainide-induced JT prolongation, T wave inversion and ventricular tachycardia during treatment for symptomatic atrial fibrillation.
    International journal of cardiology, 1994, Volume: 44, Issue:3

    Topics: Aged; Atrial Fibrillation; Electric Countershock; Electrocardiography; Female; Flecainide; Heart Con

1994
Treatment with flecainide for symptomatic and refractory tachyarrhythmias in children.
    Acta paediatrica Japonica : Overseas edition, 1994, Volume: 36, Issue:1

    Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Female; Flecainide; Humans; Infant; Injec

1994
Effect of E-4031, a new class III antiarrhythmic drug, on reentrant ventricular arrhythmias: comparison with conventional class I drugs.
    Cardiovascular drugs and therapy, 1993, Volume: 7 Suppl 3

    Topics: Animals; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Disease Models, Animal; Disopyrami

1993
Efficacy of class 1C antiarrhythmic agents in patients with inducible ventricular tachycardia refractory to therapy with class 1A antiarrhythmic drugs.
    Journal of clinical pharmacology, 1993, Volume: 33, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Benzeneacetamides; Electric Stimulation; Enc

1993
Use-dependent prolongation of ventricular tachycardia cycle length by type I antiarrhythmic drugs in humans.
    Circulation, 1993, Volume: 87, Issue:1

    Topics: Adult; Aged; Anti-Arrhythmia Agents; Electrocardiography; Female; Flecainide; Humans; Lidocaine; Mal

1993
Effects of verapamil in ventricular tachycardias. An experimental and clinical study.
    Acta cardiologica, 1997, Volume: 52, Issue:1

    Topics: Aconitine; Adult; Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Dogs; Electrocardiogr

1997
Survival in a case of life-threatening flecainide overdose.
    Intensive care medicine, 1998, Volume: 24, Issue:7

    Topics: Adolescent; Anti-Arrhythmia Agents; Bradycardia; Creatine Kinase; Drug Overdose; Electrocardiography

1998
Class IC antiarrhythmic drugs, flecainide and pilsicainide, produce ST segment elevation simulating inferior myocardial ischemia.
    Journal of cardiovascular electrophysiology, 1998, Volume: 9, Issue:8

    Topics: Anti-Arrhythmia Agents; Diagnosis, Differential; Drug Therapy, Combination; Electrocardiography; Fle

1998
ST segment elevation in the right precordial leads induced with class IC antiarrhythmic drugs: insight into the mechanism of Brugada syndrome.
    Journal of cardiovascular electrophysiology, 1999, Volume: 10, Issue:2

    Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Flecainide; Follow-Up Studies; Hea

1999
Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts.
    Journal of the American College of Cardiology, 1999, Volume: 34, Issue:7

    Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Biopsy; Child; Chromosome Aberrations; Chromosome Disorde

1999
His-Purkinje system reentry as a proarrhythmic effect of flecainide.
    Pacing and clinical electrophysiology : PACE, 2000, Volume: 23, Issue:4 Pt 1

    Topics: Administration, Oral; Aged; Ajmaline; Anti-Arrhythmia Agents; Bundle of His; Bundle-Branch Block; El

2000
Anisotropic effects of sodium channel blockers on the wavelength for ventricular excitation in dogs.
    Japanese circulation journal, 2000, Volume: 64, Issue:9

    Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disopyramide; Dogs; Electr

2000
Idiopathic sustained left ventricular tachycardia in pediatric patients.
    Pediatrics international : official journal of the Japan Pediatric Society, 2001, Volume: 43, Issue:1

    Topics: Adolescent; Anti-Arrhythmia Agents; Child; Child, Preschool; Electrophysiology; Female; Flecainide;

2001
Autonomic effects of antiarrhythmic drugs and their importance.
    European heart journal, 1992, Volume: 13 Suppl F

    Topics: Adult; Autonomic Nervous System; Cardiac Complexes, Premature; Electrocardiography; Female; Flecaini

1992
Efficacy of flecainide, sotalol, and verapamil in the treatment of right ventricular tachycardia in patients without overt cardiac abnormality.
    British heart journal, 1992, Volume: 68, Issue:4

    Topics: Adult; Aged; Electric Stimulation; Exercise Test; Flecainide; Humans; Male; Middle Aged; Sotalol; Ta

1992